Photorefractive intrastromal crosslinking for correction of hyperopia: 12-month results
Language English Country United States Media print
Document type Journal Article
PubMed
32142499
DOI
10.1097/j.jcrs.0000000000000074
PII: 02158034-202003000-00016
Knihovny.cz E-resources
- MeSH
- Photochemotherapy methods MeSH
- Photosensitizing Agents therapeutic use MeSH
- Hyperopia drug therapy metabolism physiopathology MeSH
- Collagen metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Corneal Pachymetry MeSH
- Pilot Projects MeSH
- Prospective Studies MeSH
- Cross-Linking Reagents * MeSH
- Refraction, Ocular physiology MeSH
- Riboflavin therapeutic use MeSH
- Aged MeSH
- Corneal Stroma drug effects metabolism MeSH
- Ultraviolet Rays MeSH
- Treatment Outcome MeSH
- Visual Acuity physiology MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Photosensitizing Agents MeSH
- Collagen MeSH
- Cross-Linking Reagents * MeSH
- Riboflavin MeSH
PURPOSE: To evaluate the efficacy of epithelium-on photorefractive intrastromal crosslinking (PiXL), a noninvasive procedure to reduce refractive error in patients with low hyperopia. SETTING: Gemini Eye Clinic, Zlin, Czech Republic. DESIGN: Prospective single-center study. METHODS: Twenty-two low hyperopic eyes were enrolled and underwent PiXL treatment according to a standardized treatment protocol. Visual acuity, subjective distance refraction, keratometry, topography, pachymetry, subjective discomfort, and endothelial cell density (ECD) were recorded during 12-month follow-up. RESULTS: In 22 eyes, the median manifest refraction decreased significantly (P < .0001) from +0.75 diopters (D) (interquartile range [IQR], +0.63 to +1.06 D), median and IQR) diopters (D) preoperatively to +0.25 D (IQR, 0.0 to +0.50 D) at 12-month follow-up and remained stable. Seventy-seven percent of eyes achieved refraction within ± 0.50 D of emmetropia by 1 month postoperatively and was stable through 12-month follow-up. ECD was stable and did not show significant changes. There was low incidence of postoperative pain and dry eye. CONCLUSIONS: PiXL is a promising alternative to conventional laser refractive surgeries for low hyperopia. Further studies are warranted to optimize treatment parameters for a wider range of refractive errors and to evaluate the potential to improve precision.
References provided by Crossref.org